GUANGZHOU, China --- Bio-Thera Solutions (688177:SH), a commercial-stage biopharmaceutical company developing a pipeline of innovative therapies and biosimilars, and Accord BioPharma, Inc, the U.S. specialty division ofIntas Pharmaceuticals, Ltd.(&qu...
View DetailsGuangzhou, China– June 25, 2025 – Bio-TheraSolutions Inc. (688177:SH), acommercial-stage biopharmaceutical company developing a pipeline of innovativetherapies and biosimilars, today announced that dosing has begun in a phase 3clinical study for BAT8...
· This new agreement marksthe fourth product in the partnership and introduces a potential cost-effectivealternative to oneof the world’s top-selling biologics—broadening access to specialty care forpatients with chronic inflammatory diseases. · The ...
· CHMP positive opinion is based on a robust analytical,non-clinical and clinical data package comparing to the reference product Stelara® Guangzhou,China– June , 2024 –Bio-TheraSolutions Inc.USYMRO® USYMRO®. “Bio-Therais committed to being one of th...
